ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00398372
Recruitment Status : Completed
First Posted : November 10, 2006
Last Update Posted : June 2, 2011
Sponsor:
Collaborators:
Amgen
National Institutes of Health (NIH)
Information provided by:
Stanford University

Brief Summary:
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Condition or disease Intervention/treatment Phase
Lymphoma, Non-Hodgkin Lymphomas: Non-Hodgkin Lymphomas: Non-Hodgkin Cutaneous Lymphoma Lymphomas: Non-Hodgkin Diffuse Large B-Cell Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell Lymphomas: Non-Hodgkin Mantle Cell Lymphomas: Non-Hodgkin Marginal Zone Lymphomas: Non-Hodgkin Peripheral T-Cell Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia Drug: Rituximab Drug: Epratuzumab Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Study Start Date : November 2000
Actual Primary Completion Date : June 2007
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources




Primary Outcome Measures :
  1. To characterize the molecular and cell biology of the tumor cells in lymphoma. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00398372


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Amgen
National Institutes of Health (NIH)
Investigators
Principal Investigator: Wen-Kai Weng Stanford University

Responsible Party: Wen-Kai Weng, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00398372     History of Changes
Other Study ID Numbers: LYMNHL0031
200114861
77550
CA09287
CA111827
LYMNHL0031
First Posted: November 10, 2006    Key Record Dates
Last Update Posted: June 2, 2011
Last Verified: July 2010

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Antibodies
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents